Prognostic utility of intact immunoglobulin Ig′κ/ Ig′λ ratios in multiple myeloma patients

Leukemia

Volumn 27, Issue 1, 2013, Pages 202-207

  Bradwell, A ^a,b   Harding, S ^b   Fourrier, N ^b   Mathiot, C ^c   Attal, M ^d   Moreau, P ^e   Harousseau, J L ^f   Avet Loiseau, H ^f  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b Binding Site Group Ltd   (United Kingdom)

^c INSTITUT CURIE   (France)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

immunoglobulin; multiple myeloma; prognostic factors

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN A KAPPA CHAIN; IMMUNOGLOBULIN A LAMBDA CHAIN; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; CYTOGENETICS; HEAVY CHAIN; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIGHT CHAIN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; HUMANS; IMMUNOGLOBULIN ISOTYPES; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; IMMUNOGLOBULIN LIGHT CHAINS; MULTIPLE MYELOMA; PROGNOSIS; SURVIVAL RATE;

EID: 84873567434     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2012.159     Document Type: Article

References (24)

1. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R et al. on behalf of the International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2008; 23: 215-224.
2. Anderson CL, Chaudhury C, Kim J, Bronson CL, Wani MA, Mohanty S et al. Perspective-FcRn transports albumin: relevance to immunology and medicine. Trends Immunol 2006; 27: 343-348.
3. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001; 97: 2900-2902.
4. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007; 137: 240-243.
5. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008; 22: 1933-1937.
6. Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 2004; 22: 1857-1863.
7. Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman AR et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007; 25: 4933-4937.
8. Bradwell AR, Harding SJ, Fourrier NJ, Wallis GLF, Drayson M, Carr-Smith H et al. Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem 2009; 55: 1646-1655.
9. Keren DF. Heavy/Light-chain analysis of monoclonal gammopathies. Clin Chem 2009; 55: 1606-1608.
10. Ludwig H, Harding S, Bradley C, Milosavljevich D, Drayson M, Morgan G et al. Abnormal serum IgA kappa/IgA lambda ratios at maximum response predict poor progression free survival in myeloma patients. Blood 2009; 114(abstract 4879).
11. Wechalekar A, Harding S, Lachmann H, Gillmore JD, Wassef NL, Thomas M et al. Serum immunoglobulin heavy/light chain ratios (Hevylite) in patients with systemic AL amyloidosis. Amyloid 2010; 17(abstract 186).
12. Donato L, Zeldenrust S, Murray D, Katzmann J. A 71 year old woman with multiple myeloma status after stem cell transplantation. Clin Chem 2011; 57: 1645-1649.
13. Katzmann J, Clark R, Dispenzieri A, Kyle R, Landgren O, Bradwell AR et al. Isotypespecific heavy/light chain (HLC) suppression as a predictor of myeloma development in monoclonal gammopathy of undetermined significance (MGUS). Blood 2009; 114(abstract 1788).
14. Harousseau JL, Mathiot C, Attal M, Marit D, Caillot C, Hullin T et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/1 trial. J Clin Oncol 2008; 26(abstract 8505).
15. Gonzalez-Quintela A, Alende R, Gude F, Campos J, Rey J, Meijide LM et al. Serum levels of immunoglobulins (IgG IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Imm 2007; 151: 42-50.
16. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J et al. International staging system for multiple myeloma. J Clin Oncol 2005; 23: 3412-3420.
17. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Geneviève F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum b2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
18. Alexanian R. Blood volume in monoclonal gammopathy. Blood 1977; 49: 301-307.
19. Fonseca R, Harrington D, Oken MM, Dewald GW, Bailey RJ, Van Wier SA et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (13) in multiple myeloma: an Eastern Cooperative Oncology Group Study. Cancer Res 2002; 62: 715-720.
20. Moreau P, Facon T, Leleu X, Morineau N, Huyghe P, Harousseau JL et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002; 100: 1579-1583.
21. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and-17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837-2840.
22. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007; 110: 827-832.
23. Perez-Persona E, Vidriales MB, Mateo G, Garcí-Sanz R, Mateos MV, Garcí de Coca A et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586-2592.
24. Katzmann JA, Clark RJ, Abraham RS, Bryant S, Lymp JF, Bradwell AR et al. Serum reference intervals and diagnostic ranges for free kappa and lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 28: 1437-1444.